<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05033535</url>
  </required_header>
  <id_info>
    <org_study_id>S086 Treat hypertension</org_study_id>
    <nct_id>NCT05033535</nct_id>
  </id_info>
  <brief_title>s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension</brief_title>
  <official_title>Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shenzhen People's Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shenzhen People's Hospital</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Efficacy and Safety of s086 Tablets in the Treatment of Mild to Moderate Essential&#xD;
      Hypertension:a Randomized,Double-blind,Placebo-controlled,Multicenter Phase II Clinical Trial&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 1, 2021</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Single (Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>sitting systolic blood pressure (msSBP)</measure>
    <time_frame>8 weeks after baseline</time_frame>
    <description>sitting systolic blood pressure (msSBP) at the 8th weekend from baseline</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>sitting Diastolic blood pressure (msDBP)</measure>
    <time_frame>8 weeks after baseline</time_frame>
    <description>sitting Diastolic blood pressure (msDBP) at the 8th weekend from baseline</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Compliance rate</measure>
    <time_frame>8 weeks after baseline</time_frame>
    <description>Compliance rate of pressure reduction at the 8th weekend</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Essential Hypertension</condition>
  <arm_group>
    <arm_group_label>S086</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
  </arm_group>
  <arm_group>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>S086 PLCEBO</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubatril Allisartan medoxomil</intervention_name>
    <description>Sacubatril Allisartan medoxomil ：A randomized, double-blind, placebo and positive drug parallel controlled, multi-center phase II clinical study on the effectiveness and safety of treating mild and moderate essential hypertension</description>
    <arm_group_label>S086</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Olmesartan Medoxomil</intervention_name>
    <description>Efficacy for lowering blood pressure of Olmesartan medoxomil</description>
    <arm_group_label>Olmesartan medoxomil</arm_group_label>
    <other_name>Efficacy for lowering blood pressure of Olmesartan medoxomil</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  For mild to moderate essential hypertension&#xD;
&#xD;
          -  not receiving treatment or being treated with antihypertensive drugs (single drug or&#xD;
             combination therapy of two drugs, including compound preparations containing 2 drug&#xD;
             components)&#xD;
&#xD;
          -  not receiving treatment (newly diagnosed Essential hypertension or a history of&#xD;
             hypertension but not taking any antihypertensive drugs at least 4 weeks before&#xD;
             screening), during the screening period (V1) and before randomization (V4), the mean&#xD;
             sitting systolic blood pressure (msSBP) ≥ 150mmHg and &lt;180mmHg;&#xD;
&#xD;
          -  patients who are receiving antihypertensive drugs (treated with antihypertensive drugs&#xD;
             within 4 weeks before screening), at the end of the wash period (V2), must meet the&#xD;
             average sitting systolic blood pressure ≥140mmHg and &lt;180mmHg; before randomization&#xD;
             (V4), the average sitting systolic blood pressure must be ≥150mmHg and &lt;180mmHg;&#xD;
&#xD;
          -  the patient's average sitting systolic blood pressure before randomization (V4) must&#xD;
             be the difference between the previous average sitting systolic pressure (at the end&#xD;
             of the washing period (V2)) ≤15mmHg; voluntarily participate in the trial and sign an&#xD;
             informed consent form.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Have a history of allergies to relevant components of the test drug, known or&#xD;
             suspected to be allergic to S086, sacubatril, valsartan sodium or olmesartan medoxomil&#xD;
             and related drugs (ARB, ACEI, and renin inhibitors);&#xD;
&#xD;
          -  currently in pregnancy, breastfeeding Female subjects whose pregnancy or pregnancy&#xD;
             tests are positive; or those whose subjects or their partners cannot guarantee&#xD;
             effective contraception during the trial period (acceptable methods of contraception:&#xD;
             true abstinence; intrauterine contraceptive devices; barrier contraceptives; or&#xD;
             partners accepted Sterilization surgery. Unacceptable contraceptive methods: periodic&#xD;
             abstinence, such as contraception based on calendar, ovulation, symptomatic body&#xD;
             temperature);&#xD;
&#xD;
          -  or those who have a childbirth plan within 6 months after the end of the trial;&#xD;
&#xD;
          -  have a history of drug abuse or alcohol abuse within 6 months before screening&#xD;
             History: Participated in any drug or medical device or other clinical trial within 3&#xD;
             months before screening, or participated in any drug or medical device or other&#xD;
             clinical trial during the planned trial or within 3 months after the end of the trial.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Junbo He</last_name>
    <phone>13434792084</phone>
    <email>527768709@qq.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Shenzhen People' S Hospital</name>
      <address>
        <city>Shenzhen</city>
        <state>Guangdong</state>
        <zip>518000</zip>
        <country>China</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Junbo He</last_name>
      <phone>13434792084</phone>
    </contact>
  </location>
  <location_countries>
    <country>China</country>
  </location_countries>
  <verification_date>August 2021</verification_date>
  <study_first_submitted>August 25, 2021</study_first_submitted>
  <study_first_submitted_qc>August 30, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">September 5, 2021</study_first_posted>
  <last_update_submitted>August 30, 2021</last_update_submitted>
  <last_update_submitted_qc>August 30, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">September 5, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hypertension</mesh_term>
    <mesh_term>Essential Hypertension</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Olmesartan</mesh_term>
    <mesh_term>Olmesartan Medoxomil</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

